

## Special Issue

# SARS-CoV-2 Innate and Adaptive Immune Responses

### Message from the Guest Editors

In the present issue, we will focus on studies aiming at: - Innate immune response against coronaviruses, also including ssRNA viruses belonging to other families of viruses, PRR and PAMPS identification, inflammatory response and its regulation, and virus escape strategies. - Adaptive immune responses for vaccines development against anti-SARS-CoV-2 and new strategies for vaccine development. - Tropism of coronaviruses, including the role of glycosylation. - Biochemical, structural and functional characterization of SARS-CoV-2 gene products.

---

### Guest Editors

Prof. Dr. Elmostafa Bahraoui

Institut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France

Dr. Remi Planes

IPBS, CNRS-Université Toulouse III, CNRS Toulouse, France

---

### Deadline for manuscript submissions

closed (30 April 2022)



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.8  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/si/84051](https://mdpi.com/si/84051)

*Viruses*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.8  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

---

### Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).